SOURCES SOUGHT
A -- Preclinical In Vitro and In Vivo Agent Development Assays
- Notice Date
- 9/30/2011
- Notice Type
- Sources Sought
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- N01CN25001-26
- Archive Date
- 11/1/2011
- Point of Contact
- Kathleen Y. Sears, Phone: 3014515804
- E-Mail Address
-
searsky@mail.nih.gov
(searsky@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- NOTICE INFORMATION Agency/Office: National Institutes of Health Location, National Cancer Institute, Office of Acquisitions Title: Preclinical In Vitro and In Vivo Agent Development Assays Description(s): This Small Business Sources Sought Notice (SBSS) is for information and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the National Cancer Institute (NCI). THERE IS NOT A SOLICITATION AVAILABLE. THIS IS STRICTLY MARKET RESEARCH. The purpose of this SBSS is to IDENTIFY QUALIFIED SMALL BUSINESS CONCERNS including Small Disadvantaged Businesses (SDB), Women-owned Small Business (WOSB), Historically Underutilized Business Zone (HUBZone) Small Business, Veteran-Owned Small Business (VOSB), 8(a) Small Business, and Service-Disabled Veteran-owned Small Business (SDVOSB) that are interested in and capable of performing the work described herein. Small Businesses whose size classification relative to the North American Industry Classification System (NAICS) code #541711 may consider responding to this Notice. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. The NCI does not intend to award a contract on the basis of responses nor otherwise pay for preparation of any information submitted. Preclinical In Vitro and In Vivo Agent Development Assays, a project within the Chemopreventive Agent Development Research Group (CADRG), Division of Cancer Prevention (DCP), National Cancer Institute (NCI) is seeking capability statements from all eligible Small Businesses as stated above, under NAICS Code #541711 (Research and Development in Biotechnology) with a size standard of 500 employees. The NCI, CADRG/DCP is seeking Contractors who demonstrate the ability to develop in vitro and in vivo assays for analyses of potential cancer chemopreventive agents. Summary of Project: The purpose of the anticipated requirement is 1) to identify potential cancer chemopreventive agents using mechanism-based assays in vitro that include pharmacodynamic endpoints, surrogate biomarkers; and molecular targets associated with inhibition, reversal, or delay of early carcinogenesis; 2) to further evaluate potential cancer chemopreventive agents that have been identified by mechanism-based assays in vitro or by other evidence of chemopreventive activity using standard and newly established in vivo animal models of experimental carcinogenesis. The successful Contractor shall be able to complete tasks in the following areas: A. Evaluation of Chemopreventive Agents by Screening Assays In Vitro: 1. Establish, grow, and maintain rodent, human or other primary cell cultures, cell-free systems, cell lines and tissues used in mechanism-based cell transformation studies. 2. Employ mechanism-based in vitro development systems for potential preventive agents. 3. Detect early indicators of potential efficacy of chemopreventive agents against a variety of initiating and/or promoting substances. 4. Establish assay endpoints. 5. Utilize biological reagent assays as appropriate B. Evaluation of Chemopreventive Agents Using Screening Assays In Vivo: 1. Evaluate efficacy of the agents in animal models. 2. Evaluate agents with a strong mechanistic rationale but no previous chemopreventive test results. 3. Conduct studies prior to clinical investigation of an agent in order to confirm preclinical results published in the literature. 4. Conduct organ specific carcinogenesis screening studies using animal models of chemoprevention. DURATON: It is anticipated that the ordering period for this Indefinite Delivery/Indefinite Quantity (ID/IQ) contract will be 24 months. Task Orders may extend beyond the 24 month contract period. CAPABILITY CRITERIA: Capabilities will be judged based on the following criteria: 1. Demonstration of knowledge and experience to conduct in vitro agent screening as described above. 2. Demonstration of knowledge and experience to conduct in vivo agent screening assays as described above. 3. Availability of qualified personnel 4. Availability of appropriate facilities 5. Demonstration of organizational background and experience related to this project Interested qualified small business organizations should submit a capability statement, not to exceed 15 total single-spaced pages using a 12 point font size at a minimum, that clearly details the ability to perform and that addresses the specific requirements described above. All proprietary information should be marked as such. Statements should also include an indication of current certified small business status; this indication should be clearly marked on the first page of your capability statement (preferably placed under the eligible small business concern's name and address). Responses will be reviewed only by NIH personnel and will be held in a confidential manner. Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your responses. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s). All capability statements sent in response to this SMALL BUSINESS SOURCES SOUGHT notice must be submitted electronically (via email) to Kathleen Sears, Contract Specialist at searsky@mail.nih.gov either in MS Word, Wordperfect or Adobe Portable Document Format (PDF) not later than Monday, October 17, 2011, 3:00PM EST. All responses must be received by the specified due date and time in order to be considered. ANY RESPONSES RECEIVED AFTER THAT DATE AND TIME WILL NOT BE CONSIDERED.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N01CN25001-26/listing.html)
- Record
- SN02599725-W 20111002/111001000021-37cba01a42c20d0d6e487faff7444955 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |